The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Molecular testing and managing patients with AML: advice for community clinicians
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides recommendations for clinicians outside major academic centers who manage patients with acute myeloid leukemia (AML), highlighting the importance of molecular testing to identify patients eligible for targeted therapies. Dr Marvin-Peek emphasizes the necessity of rerunning these tests at the time of diagnosis, relapse, and progression to detect potential new mutations. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
